Skip to Content

Scientists Use Gene Therapy to Tackle Oral Herpes in Mice

MONDAY, Aug. 31, 2020 -- Gene therapy has nearly eliminated the oral herpes virus in lab animals, researchers report.

Using a gene editing technique, they achieved at least a 90% reduction in latent herpes simplex virus 1 (HSV-1) in mice, which should be enough to prevent the infection from recurring.

"This is the first time that scientists have been able to go in and actually eliminate most of the herpes in a body," said senior study author Dr. Keith Jerome, a professor in the Vaccine and Infectious Disease Division at Fred Hutchinson Cancer Research Center in Seattle.

"We are targeting the root cause of the infection: the infected cells where the virus lies dormant and are the seeds that give rise to repeat infections," Jerome explained in a center news release.

In the study, the team used two sets of genetic scissors to damage the virus's DNA.

Most research on herpes has focused on suppressing the recurrence of painful symptoms. Jerome and his team said that this approach is completely different because it focuses on how to cure the disease.

"The big jump here is from doing this in test tubes to doing this in an animal," said Jerome, who also leads the virology division at University of Washington Medicine. "I hope this study changes the dialogue around herpes research and opens up the idea that we can start thinking about cure, rather than just control of the virus."

However, not all animal research pans out in humans.

The findings were published Aug. 18 in the journal Nature Communications.

Two-thirds of people worldwide younger than 50 have HSV-1, according to the World Health Organization. The lifelong infection primarily causes cold sores.

The researchers are developing a similar genetic therapy for herpes simplex 2, which causes genital herpes. They said it's likely to take at least three years before human clinical trials can be conducted to test this approach.

"This is a curative approach for both oral and genital HSV infection," said study first author Martine Aubert, a senior staff scientist at Fred Hutchinson. "I see it going into clinical trials in the near future."

© 2021 HealthDay. All rights reserved.

Read this next

U.S. to Spend $3.2 Billion to Help Develop Antiviral Pills for COVID

FRIDAY, June 18, 2021 -- After spending billions to speed the creation of COVID-19 vaccines, the United States said Thursday that it will now devote $3.2 billion to the...

Hospitals: One Reason COVID Is More Lethal for Black Americans

FRIDAY, June 18, 2021 -- Black COVID-19 patients in the United States are more likely to die than white patients, but there would be 10% fewer deaths among Black patients if they...

U.S. Supreme Court Strikes Down Challenge to Affordable Care Act

THURSDAY, June 17, 2021 -- The landmark Affordable Care Act, which has expanded health care coverage to tens of millions of Americans, has withstood a third challenge before the...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.